Brief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
20/10/2026 12:13
BRIEF-Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia Oct 20 (Reuters) - NovaBridge Biosciences NBP.O:
VISARA SECURES EXCLUSIVE OPTION FOR POTENTIAL ACQUISITION OF YOL104-2 FOR OCULAR SURFACE SQUAMOUS NEOPLASIA
NOVABRIDGE BIOSCIENCES - VISARA TO MAKE UPFRONT PAYMENT FOR EXCLUSIVE OPTION TO YOL104 PROGRAM
NOVABRIDGE BIOSCIENCES - YOLO ELIGIBLE FOR EXERCISE PAYMENT, MILESTONE PAYMENTS, AND TIERED ROYALTIES IF ACQUISITION COMPLETED
Source text: ID:nGNX474nGW
Further company coverage: NBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview